Compugen Ltd (CGEN)

[midastouch017]

Compugen-led consortium receives €3.1m grant from EU
The consortium will build a computerized model of the MAP-kinase pathway, a signaling pathway related to cancer.

Gali Weinreb 7 Mar 06 18:50

Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN) today announced that it will lead a consortium of companies and research institutes to develop a platform to simulate the MAP-kinase pathway, a signaling pathway related to cancer. The consortium has obtained a €3.1 million grant from the European Commission, including €770,000 ($930,000) for Compugen.
Other members of the consortium are Aureus Pharma of France, Consejo Superior de Investigaciones Cientificas of Spain, the Institut De Recerca Hospital Universitari Vall De Hebron from Spain, Istituto Nazionale Tumori of Milan-Italy, the Max Planck Institute for Infection Biology from Germany, the University of Glasgow, the Weizmann Institute of Science, and Arttic Israel, a consultancy and management company.

The Simulation Modeling of the MAP-kinase Pathway (SIMAP) consortium will develop a computerized model for the biochemical pathways of the MAP-kinase pathway. A number of treatments and diagnostic methods using the MAP-kinase pathway are already on the market, but it is assumed that building a computerized model of the pathway will improve understanding of it. The model is expected to help develop new drugs, improve pre-clinical and clinical trials by adapting treatments to patients’ parameters, and reduce side-effects of existing drugs.

Published by Globes [online], Israel business news - www.globes.co.il - on March 7, 2006

Dubi